Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
279 hedge funds and large institutions have $3.17B invested in Apellis Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 88 increasing their positions, 102 reducing their positions, and 48 closing their positions.
273% more call options, than puts
Call options by funds: $106M | Put options by funds: $28.3M
27% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 48
14% more capital invested
Capital invested by funds: $2.77B → $3.17B (+$402M)
3.02% more ownership
Funds ownership: 96.86% → 99.89% (+3%)
2% more funds holding
Funds holding: 273 → 279 (+6)
14% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 102
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$180M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$80.5M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$29.6M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$24.8M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$78M |
| 2 |
Jennison Associates
New York
|
-$66.7M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$51.9M |
| 4 |
Amundi
Paris,
France
|
-$34.3M |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
-$24.3M |
APLS Hedge Fund Activity: Q4 2025 in Review
279 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2025, worth a combined $3.17B — up 14% from $2.77B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new APLS positions and 48 closed out — a net gain of 13 holders — while 88 added to existing stakes and 102 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $180M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $78M sold.
- 279 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2025, up from 273 in Q3 2025.
- Funds reported $3.17B of Apellis Pharmaceuticals stock for Q4 2025, up 14% quarter-over-quarter.
- 61 funds opened new Apellis Pharmaceuticals positions in Q4 2025 and 48 closed out, a net change of +13 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2025 was RTW Investments, an estimated $180M added.
- The largest Apellis Pharmaceuticals seller in Q4 2025 was EcoR1 Capital, an estimated $78M sold.
Based on aggregated 13F filings for Q4 2025.